+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer



Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer



Journal of Oncology 2012: 862921



Background. We performed a randomized phase II study comparing efficacy and toxicity of weekly paclitaxel 80 mg/m(2) (Weetax) with three weekly docetaxel 75 mg/m(2) (Threetax), both in combination with oral capecitabine 1000 mg/m(2) twice daily for 2 weeks followed by a 1-week break. Patients. Thirty-seven women with confirmed metastatic breast cancer were randomized. Results. Median TTF was 174 (Weetax) versus 147 days (Threetax) (P=0.472). Median OS was 933 (Weetax) versus 464 days (Threetax) (P=0.191). Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax). ORR was 72% (Weetax) versus 26% (Threetax) (P = 0.01). The Threetax-combination resulted in a higher incidence of leuco-/neutropenia compared to Weetax. Grade II anemia was more pronounced in the Weetax group. No difference was found in quality of life. Conclusion. Taxanes in combination with capecitabine resulted in a high level of toxicity. Taxanes and capecitabine should be considered given sequentially and not in combination.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056909578

Download citation: RISBibTeXText

PMID: 22291703

DOI: 10.1155/2012/862921


Related references

A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast Journal 19(3): 240-249, 2013

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. Journal of Clinical Oncology 30(9): 930-935, 2012

A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer. Zhonghua Yi Xue Za Zhi 90(26): 1813-1815, 2011

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Cancer 122(20): 3119-3126, 2016

Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel and Capecitabine Plus Docetaxel in Metastatic Breast Cancer Patients in Egypt. Value in Health 17(7): A622, 2014

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters 9(2): 987-993, 2015

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clinical Breast Cancer 7(2): 141-145, 2006

Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: A randomized multicenter phase II trial. Journal of Clinical Oncology 26(15_suppl): 1119-1119, 2016

A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. Oncologist 19(5): 443-452, 2015

A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer. Journal of Clinical Oncology 23(16_suppl): 804-804, 2016

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology 24(27): 4384-4390, 2006

Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology 8(1): 76-82, 2012

O-49 A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer. European Journal of Cancer Supplements 5(3): 15-16, 2007

Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Chinese Medical Journal 123(22): 3212-3216, 2011